Xcel Energy Inc. (XEL)
NASDAQ: XEL · Real-Time Price · USD
72.39
-0.29 (-0.40%)
Aug 12, 2025, 4:00 PM - Market closed
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 12 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $76.25, which forecasts a 5.33% increase in the stock price over the next year. The lowest target is $68 and the highest is $80.
Price Target: $76.25 (+5.33%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 13 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $74 → $78 | Buy | Maintains | $74 → $78 | +7.75% | Aug 1, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $78 → $77 | Hold | Maintains | $78 → $77 | +6.37% | Jun 18, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $79 → $78 | Hold | Maintains | $79 → $78 | +7.75% | May 22, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $75 → $78 | Buy | Maintains | $75 → $78 | +7.75% | Apr 28, 2025 |
| Mizuho | Mizuho | Buy Maintains $70 → $74 | Buy | Maintains | $70 → $74 | +2.22% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
15.32B
from 13.44B
Increased by 13.95%
Revenue Next Year
16.31B
from 15.32B
Increased by 6.48%
EPS This Year
3.85
from 3.44
Increased by 11.97%
EPS Next Year
4.16
from 3.85
Increased by 8.16%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.9B | 18.8B | 19.7B | ||
| Avg | 15.3B | 16.3B | 17.3B | ||
| Low | 13.7B | 14.7B | 16.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 32.9% | 22.9% | 20.5% | ||
| Avg | 13.9% | 6.5% | 6.3% | ||
| Low | 1.8% | -3.9% | -1.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.04 | 4.41 | 4.85 | ||
| Avg | 3.85 | 4.16 | 4.50 | ||
| Low | 3.69 | 3.91 | 4.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 17.6% | 14.5% | 16.5% | ||
| Avg | 12.0% | 8.2% | 8.0% | ||
| Low | 7.4% | 1.6% | 0.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.